Dr. Reddy’s Laboratories rose 2.4% after brokerages termed higher volume growth in the September quarter, new launches and a ...

RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time ...

Dr. Reddy’s (DRRD) Q2FY25 EBITDA was largely in line with our estimate. The base business margins and US sales ex of ...

Hyderabad-based Dr Reddy’s Laboratories (DRL) recorded a 9.5 per cent decline in its consolidated profit after tax (PAT), ...

Indian pharmaceutical major, Dr Reddy’s Laboratories share surged 3.1 per cent at Rs 1,312 a piece on the BSE in Wednesday’s intraday deals. This came after the pharma major on Tuesday recorded its ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report), ...

Dr. Reddy’s Laboratories’ (DRL) Q2FY25 performance, adjusted for acquisition-related expenses (INR 561mn) and impairment ...

Indian generic drugmaker Dr Reddy's Laboratories recorded a 9.5 percent decline in its consolidated net profit after tax to ...

Dr. Reddy's Laboratories Ltd. 500124 shares advanced 2.39% to 1,303.00 Indian rupees Wednesday, on what proved to be an ...

Our Bureau, New Delhi Wednesday, November 6, 2024, 13:45 Hrs [IST] Dr Reddy's Laboratories has reported a decline of 9.36 pe ...

Systematix upgraded the stock rating to 'hold' and hiked target price to Rs 1,414 apiece, while Dolat Capital upgraded rating ...

The pharma major announced its Q2 earnings for the financial year 2024-25 on Tuesday. Shares of Dr Reddy's Laboratories ...